Northwestern Medicine scientists have discovered that an FDA-approved compound promotes neuroprotective effects in experimental models of Parkinson’s disease. The compound, N-acetyl-L-leucine (NALL), simultaneously targets multiple molecular…
Category: 8. Health
-
FDA-approved compound promotes neuroprotective effects in Parkinson's disease
-
Trump Threatens to Do Something Horrible in Africa Unless He Gets a Deal on Precious Minerals
Donald Trump has been busy in Africa. Look no further than airstrikes in Nigeria, travel bans on…
Continue Reading
-
New study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment
A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that…
Continue Reading
-
Erratum for the Research Article “ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes” | Science Translational Medicine
The Research Article “ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes” by Y. Grobs et al. did not include the source of some samples when it was initially…
Continue Reading
-
Blood-brain barrier disruption, traumatic encephalopathy, and cognitive decline in retired athletes | Science Translational Medicine
Blood-brain barrier disruption is associated with cognitive decline and complement system activation in retired athletes.
Continue Reading
-
Disruption of the oligodendroglial miR-126a-3p–Pex5 axis inhibits remyelination in chronic demyelinating lesions | Science Translational Medicine
Dysregulation of the oligodendroglial miR-126a-3p–Pex5 axis represents a targetable barrier to remyelination in chronic multiple sclerosis lesions.
Continue Reading
-
Lowering the HTT1a transcript as an effective therapy for Huntington’s disease in a knockin mouse model | Science Translational Medicine
Lowering the HTT1a transcript delays the onset of molecular and neuropathological phenotypes in a knockin mouse model of Huntington’s disease.
Continue Reading
-
Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies | Science Translational Medicine
A cohort of 60 mouse-intraductal patient-derived xenograft models of primary invasive breast cancer was developed to develop neoadjuvant treatments.
Continue Reading
-
Selective targeting of mutant huntingtin intron 1 improves rescue provided by antisense oligonucleotides in Huntington’s disease mice | Science Translational Medicine
Selective lowering of mHtt and Htt1a is superior to nonselective lowering of Htt in rescuing aggregate formation and transcriptional dysregulation.
Continue Reading
-
Amyloid-β as a target to suppress tonic PTH hypersecretion in hyperparathyroidism due to vitamin D deficiency | Science Translational Medicine
Blocking aberrant signaling of Aβ, GABAB1R/CaSR dimer, and Tau suppresses tonic PTH hypersecretion in hyperparathyroidism due to vitamin D deficiency.
Continue Reading